CN102488681B - 布洛芬苯海拉明口腔崩解片及其制备方法 - Google Patents
布洛芬苯海拉明口腔崩解片及其制备方法 Download PDFInfo
- Publication number
- CN102488681B CN102488681B CN 201110432648 CN201110432648A CN102488681B CN 102488681 B CN102488681 B CN 102488681B CN 201110432648 CN201110432648 CN 201110432648 CN 201110432648 A CN201110432648 A CN 201110432648A CN 102488681 B CN102488681 B CN 102488681B
- Authority
- CN
- China
- Prior art keywords
- ibuprofen
- diphenhydramine
- recipe quantity
- oral cavity
- aspartame
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229960001680 ibuprofen Drugs 0.000 title claims abstract description 81
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 title claims abstract description 80
- 229960000520 diphenhydramine Drugs 0.000 title claims abstract description 51
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 title claims 6
- 239000006191 orally-disintegrating tablet Substances 0.000 title abstract 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 30
- 108010011485 Aspartame Proteins 0.000 claims abstract description 27
- 239000000605 aspartame Substances 0.000 claims abstract description 27
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical group OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims abstract description 27
- 235000010357 aspartame Nutrition 0.000 claims abstract description 27
- 229960003438 aspartame Drugs 0.000 claims abstract description 27
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 22
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims abstract description 20
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical group [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims abstract description 20
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims abstract description 20
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims abstract description 20
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims abstract description 20
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 19
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims abstract description 19
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract description 19
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract description 19
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 19
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 19
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 19
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims abstract description 18
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 15
- 229930195725 Mannitol Natural products 0.000 claims abstract description 15
- 239000000594 mannitol Substances 0.000 claims abstract description 15
- 235000010355 mannitol Nutrition 0.000 claims abstract description 15
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 11
- 235000017557 sodium bicarbonate Nutrition 0.000 claims abstract description 10
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims abstract description 10
- 239000004094 surface-active agent Substances 0.000 claims abstract description 10
- 239000000203 mixture Substances 0.000 claims description 43
- 210000000214 mouth Anatomy 0.000 claims description 39
- 239000008187 granular material Substances 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 claims description 19
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 18
- 229960003943 hypromellose Drugs 0.000 claims description 17
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 claims description 17
- 239000000080 wetting agent Substances 0.000 claims description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 13
- 238000004090 dissolution Methods 0.000 claims description 13
- 239000007779 soft material Substances 0.000 claims description 8
- 206010013786 Dry skin Diseases 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 229960001855 mannitol Drugs 0.000 claims description 4
- 229960001407 sodium bicarbonate Drugs 0.000 claims description 2
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 abstract description 67
- 229960001583 diphenhydramine citrate Drugs 0.000 abstract description 23
- 239000003795 chemical substances by application Substances 0.000 abstract description 20
- 239000002253 acid Substances 0.000 abstract description 10
- 239000007884 disintegrant Substances 0.000 abstract description 10
- 229920000881 Modified starch Polymers 0.000 abstract description 8
- 229920002472 Starch Polymers 0.000 abstract description 7
- 239000008107 starch Substances 0.000 abstract description 7
- 235000019698 starch Nutrition 0.000 abstract description 7
- 239000000945 filler Substances 0.000 abstract description 6
- 239000011734 sodium Substances 0.000 abstract description 6
- 229910052708 sodium Inorganic materials 0.000 abstract description 6
- 239000000314 lubricant Substances 0.000 abstract description 5
- 229920002785 Croscarmellose sodium Polymers 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 abstract description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 abstract 2
- 239000000853 adhesive Substances 0.000 abstract 2
- 230000001070 adhesive effect Effects 0.000 abstract 2
- 235000003599 food sweetener Nutrition 0.000 abstract 2
- 239000002304 perfume Substances 0.000 abstract 2
- 239000003765 sweetening agent Substances 0.000 abstract 2
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 abstract 1
- 239000000084 colloidal system Substances 0.000 abstract 1
- 229960000913 crospovidone Drugs 0.000 abstract 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 abstract 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 abstract 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 239000000377 silicon dioxide Substances 0.000 abstract 1
- 235000015424 sodium Nutrition 0.000 abstract 1
- 230000036407 pain Effects 0.000 description 21
- 208000002193 Pain Diseases 0.000 description 20
- 239000000470 constituent Substances 0.000 description 12
- 239000000686 essence Substances 0.000 description 12
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 9
- 229940082170 ibuprofen 200 mg Drugs 0.000 description 8
- 208000019116 sleep disease Diseases 0.000 description 8
- 208000020685 sleep-wake disease Diseases 0.000 description 8
- 235000021355 Stearic acid Nutrition 0.000 description 7
- 239000001768 carboxy methyl cellulose Substances 0.000 description 7
- 238000004132 cross linking Methods 0.000 description 7
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 7
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 7
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 7
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000008117 stearic acid Substances 0.000 description 7
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 6
- 229940118682 diphenhydramine citrate 38 mg Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 235000019640 taste Nutrition 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 235000006679 Mentha X verticillata Nutrition 0.000 description 4
- 235000002899 Mentha suaveolens Nutrition 0.000 description 4
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 239000003507 refrigerant Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000007958 sleep Effects 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 201000003152 motion sickness Diseases 0.000 description 3
- 230000008058 pain sensation Effects 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 101100203596 Caenorhabditis elegans sol-1 gene Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 208000027520 Somatoform disease Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- -1 methyl phenyl ethers anisoles Chemical class 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000001473 noxious effect Effects 0.000 description 2
- 208000027753 pain disease Diseases 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 235000019605 sweet taste sensations Nutrition 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000017164 Chronobiology disease Diseases 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- XINCECQTMHSORG-UHFFFAOYSA-N Isoamyl isovalerate Chemical compound CC(C)CCOC(=O)CC(C)C XINCECQTMHSORG-UHFFFAOYSA-N 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000006199 Parasomnias Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 206010048908 Seasonal allergy Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229960002887 deanol Drugs 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 108010017796 epoxidase Proteins 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000000938 histamine H1 antagonist Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000008518 non respiratory effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008533 pain sensitivity Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- KEAYESYHFKHZAL-IGMARMGPSA-N sodium-23 atom Chemical compound [23Na] KEAYESYHFKHZAL-IGMARMGPSA-N 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
组分 | 质量(g) | 质量百分比(%) |
布洛芬 | 200 | 40 |
枸橼酸苯海拉明 | 38 | 7.6 |
微晶纤维素 | 120 | 24 |
甘露醇 | 70 | 14 |
交联聚维酮 | 40 | 8 |
羟丙甲纤维素 | 7.5 | 1.5 |
十二烷基硫酸钠 | 10 | 2 |
硬脂酸 | 5 | 1 |
胶体二氧化硅 | 1.5 | 0.3 |
阿司帕坦 | 6.5 | 1.3 |
薄荷香精 | 1.5 | 0.3 |
总重 | 500 | 100 |
组分 | 质量(g) | 质量百分比(%) |
布洛芬 | 200 | 40 |
盐酸苯海拉明 | 25 | 5 |
微晶纤维素 | 125 | 25 |
甘露醇 | 62.5 | 12.5 |
交联聚维酮 | 30 | 6 |
枸橼酸 | 15 | 3 |
碳酸氢钠 | 10 | 2 |
羟丙甲纤维素 | 5 | 1 |
十二烷基硫酸钠 | 7.5 | 1.5 |
硬脂酸镁 | 6 | 1.2 |
胶体二氧化硅 | 1 | 0.2 |
阿司帕坦 | 7.5 | 1.5 |
甜菊素 | 3.5 | 0.7 |
柠檬香精 | 2 | 0.4 |
总重 | 500 | 100 |
组分 | 质量(g) | 质量百分比(%) |
布洛芬 | 200 | 40 |
枸橼酸苯海拉明 | 38 | 7.6 |
微晶纤维素 | 105 | 21 |
甘露醇 | 87 | 17.4 |
交联羧甲基纤维素钠 | 42 | 8.4 |
羟丙甲基纤维素 | 5.5 | 1.1 |
十二烷基硫酸钠 | 12.5 | 2.5 |
硬脂酸镁 | 5 | 1.0 |
胶体二氧化硅 | 1 | 0.2 |
阿司帕坦 | 4 | 0.8 |
总重 | 500 | 100 |
组分 | 质量(g) | 质量百分比(%) |
布洛芬 | 200 | 40 |
枸橼酸苯海拉明 | 38 | 7.6 |
微晶纤维素 | 150.5 | 30.1 |
预胶化淀粉 | 46.5 | 9.3 |
交联聚维酮 | 30.5 | 6.1 |
枸橼酸 | 5 | 1 |
碳酸氢钠 | 5 | 1 |
羟丙甲纤维素 | 6 | 1.2 |
十二烷基硫酸钠 | 6 | 1.2 |
硬脂酸 | 3.5 | 0.7 |
胶体二氧化硅 | 1.5 | 0.3 |
阿司帕坦 | 6 | 1.2 |
甜菊素 | 1.5 | 0.3 |
总重 | 500 | 100 |
组分 | 质量(g) | 质量百分比(%) |
布洛芬 | 200 | 40 |
枸橼酸苯海拉明 | 38 | 7.6 |
微晶纤维素 | 140 | 28 |
预胶化淀粉 | 36 | 7.2 |
交联羧甲纤维素钠 | 33.5 | 6.7 |
羧甲基淀粉钠 | 23 | 4.6 |
羟丙甲纤维素 | 7.7 | 1.54 |
十二烷基硫酸钠 | 11 | 2.2 |
硬脂酸镁 | 5.2 | 1.04 |
胶体二氧化硅 | 0.9 | 0.18 |
阿司帕坦 | 3.55 | 0.71 |
甜菊素 | 1.15 | 0.23 |
总重 | 500 | 100 |
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110432648 CN102488681B (zh) | 2011-12-21 | 2011-12-21 | 布洛芬苯海拉明口腔崩解片及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110432648 CN102488681B (zh) | 2011-12-21 | 2011-12-21 | 布洛芬苯海拉明口腔崩解片及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102488681A CN102488681A (zh) | 2012-06-13 |
CN102488681B true CN102488681B (zh) | 2013-03-13 |
Family
ID=46180588
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201110432648 Expired - Fee Related CN102488681B (zh) | 2011-12-21 | 2011-12-21 | 布洛芬苯海拉明口腔崩解片及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102488681B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017105852A1 (en) * | 2015-12-18 | 2017-06-22 | The Procter & Gamble Company | Quick dissolving diphenhydramine oral dosage form |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2014233139A1 (en) * | 2013-03-15 | 2016-01-21 | Mylan Inc. | Manufacturing process for effervescent dosage forms |
CN105476971A (zh) * | 2016-01-19 | 2016-04-13 | 海南高升医药科技开发股份有限公司 | 一种治疗感冒药的药物组合物及其制备方法 |
EP3398590A1 (de) * | 2017-05-02 | 2018-11-07 | Stada Arzneimittel Ag | Schmelztablette, enthaltend ein h1-antihistaminika |
CN110859815A (zh) * | 2019-12-05 | 2020-03-06 | 远大医药(中国)有限公司 | 一种甲硝唑制剂及制备方法 |
CN113133979A (zh) * | 2020-01-20 | 2021-07-20 | 亚宝药业太原制药有限公司 | 一种口味改善的乳酸菌素片 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101528205A (zh) * | 2006-10-25 | 2009-09-09 | 麦克内尔-Ppc股份有限公司 | 布洛芬组合物 |
CN101641085A (zh) * | 2007-03-24 | 2010-02-03 | 雷克特本克斯尔保健(英国)有限公司 | 具有至少两种活性物的稳定性改进的片剂 |
CN101951767A (zh) * | 2007-12-10 | 2011-01-19 | 欧兰德股份有限公司 | 包含苯海拉明的口服崩解片剂 |
-
2011
- 2011-12-21 CN CN 201110432648 patent/CN102488681B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101528205A (zh) * | 2006-10-25 | 2009-09-09 | 麦克内尔-Ppc股份有限公司 | 布洛芬组合物 |
CN101641085A (zh) * | 2007-03-24 | 2010-02-03 | 雷克特本克斯尔保健(英国)有限公司 | 具有至少两种活性物的稳定性改进的片剂 |
CN101951767A (zh) * | 2007-12-10 | 2011-01-19 | 欧兰德股份有限公司 | 包含苯海拉明的口服崩解片剂 |
Non-Patent Citations (4)
Title |
---|
可用于口腔崩解片的新型崩解剂研究概况;孙冠男等;《中国药房》;20081231;第19卷(第31期);第2459页右栏第3段 * |
孙冠男等.可用于口腔崩解片的新型崩解剂研究概况.《中国药房》.2008,第19卷(第31期),第2458-2460页. |
孙敬田.布洛芬口腔崩解片的研制.《齐鲁药事》.2005,第24卷(第10期),第620-622页. |
布洛芬口腔崩解片的研制;孙敬田;《齐鲁药事》;20051031;第24卷(第10期);第620页左栏第1段,第621页右栏第4段 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017105852A1 (en) * | 2015-12-18 | 2017-06-22 | The Procter & Gamble Company | Quick dissolving diphenhydramine oral dosage form |
US9855227B2 (en) | 2015-12-18 | 2018-01-02 | The Procter & Gamble Company | Quick dissolving diphenhydramine oral dosage form |
US10085954B2 (en) | 2015-12-18 | 2018-10-02 | The Procter & Gamble Company | Quick dissolving diphenhydramine oral dosage form |
Also Published As
Publication number | Publication date |
---|---|
CN102488681A (zh) | 2012-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102488681B (zh) | 布洛芬苯海拉明口腔崩解片及其制备方法 | |
JP4989733B2 (ja) | 口腔内崩壊錠 | |
JP4656672B2 (ja) | イミダフェナシンを有効成分とする口腔内速崩錠の製造方法 | |
CN102579415B (zh) | 一种含有阿戈美拉汀的口腔粘膜或舌下给药的药物组合物 | |
PT1800669E (pt) | Composição farmacêutica oralmente dispersável para a administração de agomelatina por via oral, oromucosal ou sublingual | |
CN105534933A (zh) | 一种沃替西汀口腔崩解片及其制备方法 | |
CN102716097A (zh) | 控制口腔崩解片药物释放速率的方法 | |
KR102246657B1 (ko) | 타다라필 및 탐수로신을 함유하는 약학적 캡슐 복합 제제 | |
CN101904827A (zh) | 盐酸氨溴索口腔崩解片及其制备方法 | |
CN102440973B (zh) | 枸橼酸苯海拉明口腔崩解片及其制备方法 | |
CN112426408B (zh) | 一种褪黑素组合物及其制备工艺 | |
CN101264080A (zh) | 一种含有右旋氯苯那敏的药用组合物及其制备方法 | |
CN102488680B (zh) | 布洛芬苯海拉明分散片及其制备方法 | |
JP5452050B2 (ja) | イミダフェナシンを含有する口腔内崩壊錠 | |
CN101690720A (zh) | 盐酸卡替洛尔口腔崩解片及其制备方法 | |
CN101797237A (zh) | 甲磺酸倍他司汀口腔崩解片及其制备方法 | |
CN100417392C (zh) | 一种感冒制剂泡腾片及其制备方法 | |
CN104523717A (zh) | 西甲硅油奥替溴铵咀嚼片及其制备方法 | |
CN103156817A (zh) | 经口腔粘膜吸收的利扎曲坦药物 | |
CN101797236A (zh) | 重酒石酸卡巴拉汀口腔崩解片及其制备方法 | |
CN101797235B (zh) | 卡络磺钠口腔崩解片及其制备方法 | |
CN102440971A (zh) | 伊潘立酮口腔崩解片 | |
CN101375852B (zh) | 富马酸喹硫平口服制剂及其制备方法 | |
JP2006527064A (ja) | β−ラクタム系抗生物質を含む懸濁錠剤及びその製造方法 | |
WO2013080271A1 (ja) | 鎮痛剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP02 | Change in the address of a patent holder | ||
CP02 | Change in the address of a patent holder |
Address after: 402460 No. 160 Changyuan Street College Road, Rongchang District, Chongqing Patentee after: SOUTHWEST University Address before: No. 1, natural road, Beibei District, Chongqing Patentee before: Southwest University |
|
CP02 | Change in the address of a patent holder | ||
CP02 | Change in the address of a patent holder |
Address after: 400715 No. 1 Tiansheng Road, Beibei District, Chongqing Patentee after: SOUTHWEST University Address before: 402460 No. 160 Changyuan Street College Road, Rongchang District, Chongqing Patentee before: Southwest University |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130313 |